| Literature DB >> 31736691 |
Xianhui Kang1,2, Ziyi Zuo3, Wandong Hong4, Hongli Tang1, Wujun Geng1.
Abstract
Exosomes, as a type of extracellular vesicle (EV), are lipid bilayer vesicles 20-100 nm in diameter that can cross the blood-brain barrier. Exosomes are important transport vesicles in the human body that participate in many conduction pathways and play an important physiological role. Because of their high biocompatibility and low immunogenicity and toxicity, exosomes have attracted increasing attention as an attractive drug delivery system. This article reviews the relevant studies that have shown that exosomes play an important role in protective mechanisms against ischemic brain injury.Entities:
Keywords: brain protection; drug delivery; exosomes; ischemic brain injury; stroke
Year: 2019 PMID: 31736691 PMCID: PMC6828609 DOI: 10.3389/fnins.2019.01149
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
FIGURE 1The biogenesis and composition of exosomes. Exosomes originate as endocytic vesicles through invagination of the cell membrane, which results in the formation of early exosomes and, subsequently, late exosome called MVBs. MVBs contain ILV which are formed from budding of the endosomal membrane and are called exosomes. When MVBs fuse with the plasma membrane, they give rise to the release of exosomes into the extracellular space. (A) Endosomal proteins such as CD9, Alix, and TSG101 may be incorporated into exosomes during their assembly to facilitate this process. (B) AGO2 and GW182 are two important components of the RNA-induced silencing complex (RISC), which associate with MVBs so as to mediate miRNA sorting into exosomes. (C) Subsequent fusion of cell-derived exosomes with the plasma membrane through their CD9 (tetraspanin) interaction with surface glycoproteins on target cells gives rise to cytosolic delivery of the siRNA directly. This process is involved in the creation of temporary RNAi. (D) Exosomes originate from inward budding in the lumen of the MVB through which the cytoplasmic content from the cell of origin and also viral components, including mRNA and small non-coding RNA and viral glycoproteins are incorporated into the exosome, and then released as a selective cargo in viral-infected cells. These virus-modified exosomes display the original surface markers and cell membrane as the parent cells. (E) Bioengineered or virus-modified exosomes are designed to express a selective set of proteins and small, non-coding RNAs to target specific receptors. Exosomes then fuse with the endosomal membrane to release their non-coding RNAs into the cytoplasm so as to load siRNA into the RNAi (RISC) complex of the target cells in order to prevent mRNA translation into protein. Acronyms: RISC, RNA-induced silencing complex; RNAi, RNA interference; siRNA, small interference RNA; MVBs, multivesicular bodies.
FIGURE 2Exosomes play roles in drug delivery: exosomes isolated from different cell types are rich in miRNA, RNA and protein. These molecules can further modified and reinserted into the exosomes for different therapeutic applications.
Dosages and routes of administration of exosomes in animal experiments.
| Intranasal (IN) | 15 μg | 7.5 × 109 exosomes | |
| Intranasal (IN) | 10 μg | – | |
| Tail vein injection (TV) | 100 μg | 3 × 109 exosomes | |
| Intravenous injection (IV) | 250 μL | EVs released by 2 × 106 MSCs | |
| Tail vein injection (TV) | 100 μg | – | |
| Tail vein injection (TV) | 100 μg/day for 3 days | – | |
| Tail vein injection (TV) | 100 μg | – |